Download PDF
Thromb Haemost 2009; 102(04): 790-792
DOI: 10.1160/TH09-02-0135
Letters to the Editor
Schattauer GmbH

Fibrin gel structure obtained with a FVIIa analogue with enhanced FX-activating potential in haemophilia

Shu He
1   Department of Clinical Sciences, Danderyds Hospital Karolinska Institutet, Stockholm, Sweden
2   Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
,
Mirella Ezban
3   Biopharmaceuticals Research Unit, Novo Nordisk A/S, Novo Nordisk Park, Måløv, Denmark
,
Niklas Bark
2   Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
4   Department of linical Neuroscience, Karolinska Institutet, Stockholm, Sweden;
,
Egon Persson
3   Biopharmaceuticals Research Unit, Novo Nordisk A/S, Novo Nordisk Park, Måløv, Denmark
,
Ulla Hedner
3   Biopharmaceuticals Research Unit, Novo Nordisk A/S, Novo Nordisk Park, Måløv, Denmark
5   University of Lund, Sweden
› Author AffiliationsGrants/financial support: This study was partly funded by a research grant from Novo Nordisk A/S
Further Information

Publication History

Received: 03 July 2009

Accepted after major revision: 07 July 2009

Publication Date:
24 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Blombäck B. Fibrinogen and fibrin – proteins with complex roles in hemostasis and thrombosis. Thromb Res 1996; 83: 1-75.
    CrossrefPubMedGoogle Scholar
  • 2 Wolberg AS, Allen GA, Monroe DM. et al. High dose factor VIIa improves clot structure and stability in a model of haemophilia B. Br J Haematol 2005; 131: 645-655.
    CrossrefPubMedGoogle Scholar
  • 3 Lisman T, Weeterings C, de Groot PG. Platelet aggregation: involvement of thrombin and fibrin(ogen). Front Biosci 2005; 10: 2504-2517.
    CrossrefPubMedGoogle Scholar
  • 4 Blombäck B, Carlsson K, Fatah K. et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538.
    CrossrefPubMedGoogle Scholar
  • 5 Monroe DM, Hoffman M, Oliver JA. et al. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-547.
    CrossrefPubMedGoogle Scholar
  • 6 He S, Blombäck M, Jacobsson GEkman. et al. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX. J Thromb Haemost 2003; 01: 1215-1219.
    CrossrefPubMedGoogle Scholar
  • 7 He S, Ekman GJ, Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost 2005; 03: 272-279.
    CrossrefPubMedGoogle Scholar
  • 8 Hedner U, Ingerslev J. Clinical use of recombinant FVIIa (rFVIIa). Transfus Sci 1998; 19: 163-176.
    CrossrefPubMedGoogle Scholar
  • 9 Hedner U, Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annu Rev Med 2008; 59: 29-41.
    CrossrefPubMedGoogle Scholar
  • 10 Poon MC, D´Oiron R, Von Depka M. et al. International Data Collection on Recombinant Factor VIIa and Congenital Platelet Disorders Study Group. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann’s thrombasthenia: results of an international survey. J Thromb Haemost 2004; 02: 1096-1103.
    CrossrefPubMedGoogle Scholar
  • 11 Croom KF, McCormack PL. Recombinant factor VIIa (eptacog alfa). A review of its use in congenital hemophilia with inhibitors, acquired hemophilia, and other congenital bleeding disorders. Biodrugs 2008; 22: 121-136.
    CrossrefPubMedGoogle Scholar
  • 12 Treur MJ, McCracken F, Heeg B. et al. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors; a Bayesian meta-regression. Haemophilia 2009; 15: 420-436.
    CrossrefPubMedGoogle Scholar
  • 13 Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci USA 2001; 98: 13583-13588.
    CrossrefPubMedGoogle Scholar
  • 14 Rand KD, Andersen MD, Olsen OH. et al. The origins of enhanced activity in factor VIIa analogs and the interplay between key allosteric sites revealed by hydrogen exchange mass spectrometry. J Biol Chem 2008; 283: 13378-13387.
    CrossrefPubMedGoogle Scholar
  • 15 Allen GA, Persson E, Campbell RA. et al. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 27: 683-689.
    CrossrefPubMedGoogle Scholar
  • 16 Sørensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007; 137: 158-165.
    CrossrefPubMedGoogle Scholar
  • 17 Hedner U. Recombinant factor VIIa: its background, development and clinical use. Curr Opin Hematol 2007; 04: 225-229.
    PubMedGoogle Scholar
  • 18 Brophy DF, Martin EJ, Nolte ME. et al. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia 2007; 13: 533-541.
    CrossrefPubMedGoogle Scholar
  • 19 Lisman T, De Groot PG, Lambert T. et al. Enhanced in vitro procoagulant and antifibrinolytic potential of superactive variants of recombinant factor VIIa in severe hemophilia A. J Thromb Haemost 2003; 01: 2175-2178.
    CrossrefPubMedGoogle Scholar
  • 20 Carr Jr ME, Martin EJ. Evolving techniques for monitoring clotting in plasma and whole blood samples. Clin Lab 2004; 50: 539-549.
    PubMedGoogle Scholar
  • 21 He S, Cao H, Antovic A. et al. Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials. Blood Coagul Fibrinolysis 2005; 16: 61-67.
    CrossrefPubMedGoogle Scholar